No profile data available.
CG Oncology, Inc. (CGON) is a healthcare company in the additional cancer treatment drugs industry, based in Dallas, United States, with about 142 full-time employees.
It reported revenue of $4.04 million for fiscal year 2025, up 254.7% from fiscal year 2024, and net income of -$161.00 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $1.16 million. Its market capitalization was $5.66 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CG Oncology reported $4.04 million in revenue for fiscal year 2025, up 254.7% from $1.14 million in fiscal year 2024. In Q2 2026 revenue was $1.16 million.
$5.66 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Halozyme Therapeutics, Inc. (HALO), ImmunityBio, Inc. (IBRX), Iovance Biotherapeutics, Inc. (IOVA), Erasca, Inc. (ERAS).